EPIX Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics through the use of its proprietary silico drug discovery platform. The company’s therapeutic product candidates in development include PRX-08066 that completed Phase IIa clinical trial for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease; PRX-03140, which is in Phase IIa clinical trial for the treatment of Alzheimer's disease; PRX-00023, which is in Phase IIb clinical trial for the treatment of depressive disorder; and PRX-07034, which is in Phase Ib clinical trial for the treatment of obesity and cognitive impairment associated with schizophrenia. Its imaging agents comprise Vasovist, an injectable intravascular contrast agent that provides enhanced imaging of the vascular system using magnetic resonance angiography; and EP-2104R that enables the identification of blood clots using MRI. EPIX Pharmaceuticals has collaborations with SmithKline Beecham Corporation; Amgen, Inc.; Cystic Fibrosis Foundation Therapeutics Incorporated; and Bayer Schering Pharma AG, Germany. The company was founded in 1988 as Metacorp, Inc. and changed its name to METASYN, Inc. in May 1989. It further changed its name to EPIX Medical, Inc. in May 1996 and then to EPIX Pharmaceuticals Inc. in September 2004. EPIX Pharmaceuticals Inc. is headquartered in Lexington, Massachusetts.